Grandeur Peak Global Advisors LLC lifted its holdings in shares of AtriCure, Inc. (NASDAQ:ATRC – Free Report) by 53.8% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 587,399 shares of the medical device company’s stock after buying an additional 205,497 shares during the period. AtriCure makes up about 4.0% of Grandeur Peak Global Advisors LLC’s portfolio, making the stock its 6th biggest holding. Grandeur Peak Global Advisors LLC’s holdings in AtriCure were worth $16,435,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently added to or reduced their stakes in the business. Geneos Wealth Management Inc. acquired a new stake in AtriCure in the 2nd quarter valued at $37,000. Smartleaf Asset Management LLC raised its position in AtriCure by 59.8% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock valued at $46,000 after purchasing an additional 429 shares during the period. Harbor Investment Advisory LLC acquired a new position in shares of AtriCure during the second quarter worth about $40,000. Allworth Financial LP purchased a new stake in shares of AtriCure in the second quarter worth about $43,000. Finally, Fifth Third Bancorp purchased a new stake in shares of AtriCure in the first quarter worth about $51,000. 99.11% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently issued reports on the company. BTIG Research increased their target price on AtriCure from $45.00 to $55.00 and gave the company a “buy” rating in a research note on Monday, August 24th. Canaccord Genuity Group boosted their price target on AtriCure from $53.00 to $55.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. Zacks Research downgraded shares of AtriCure from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 24th. UBS Group dropped their price objective on shares of AtriCure from $55.00 to $50.00 and set a “buy” rating on the stock in a research note on Tuesday, July 28th. Finally, Weiss Ratings raised shares of AtriCure from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, August 19th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $49.89.
Insider Activity at AtriCure
In related news, insider Vinayak Doraiswamy sold 6,000 shares of AtriCure stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $38.88, for a total value of $233,280.00. Following the completion of the sale, the insider owned 86,511 shares in the company, valued at approximately $3,363,547.68. The trade was a 6.49% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Karen Prange sold 3,564 shares of the company’s stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $38.80, for a total transaction of $138,283.20. Following the completion of the sale, the director directly owned 22,809 shares in the company, valued at $884,989.20. This represents a 13.51% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 53,616 shares of company stock worth $2,149,994. 4.00% of the stock is currently owned by insiders.
AtriCure Stock Performance
NASDAQ:ATRC opened at $48.54 on Monday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.19 and a current ratio of 4.22. AtriCure, Inc. has a one year low of $25.36 and a one year high of $49.98. The business’s 50-day simple moving average is $37.89 and its 200 day simple moving average is $32.22. The stock has a market cap of $2.47 billion, a price-to-earnings ratio of 231.15 and a beta of 1.20.
AtriCure (NASDAQ:ATRC – Get Free Report) last issued its quarterly earnings results on Thursday, July 23rd. The medical device company reported $0.18 EPS for the quarter. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.The firm had revenue of $153.60 million during the quarter, compared to the consensus estimate of $151.80 million. During the same quarter in the prior year, the business posted ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, sell-side analysts predict that AtriCure, Inc. will post 0.29 earnings per share for the current fiscal year.
AtriCure Profile
AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.
The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.
Featured Articles
- Five stocks we like better than AtriCure
- Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally
- Rubrik’s AI Security Bet Could Power the Next Leg Higher
- Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All
- Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against?
Want to see what other hedge funds are holding ATRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AtriCure, Inc. (NASDAQ:ATRC – Free Report).
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.
